Sarepta Therapeutics (SRPT) Stock Price, Quote & News

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dy...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 274 4000

Website: www.sarepta.com

Address:

215 First Street, Suite 415, Cambridge, United States

joselito_dominguez Feb. 4 at 8:27 AM

$SRPT If you’re invested in SRPT, the thesis is simple: execution + evidence. More long-term data, smarter risk management, and steady delivery.

0 · Reply

StocksCryptoNews Feb. 4 at 2:37 AM

$SRPT Sarepta Therapeutics, Inc. Stock Analysis: A Closer Look at Its 5.38% Potential Upside https://www.directorstalkinterviews.com/sarepta-therapeutics-inc-srpt-stock-analysis-a-closer-look-at-its-5-38-potential-upside/4121237909

0 · Reply

Maniacal_Laugh Feb. 4 at 2:26 AM

$SRPT they are both manipulating and naked shorting to keep a lid on the price

0 · Reply

Maniacal_Laugh Feb. 4 at 1:19 AM

$SRPT so in this case, a person just takes advantage of the manipulation

1 · Reply

Maniacal_Laugh Feb. 4 at 1:16 AM

$SRPT The real problem isnt the data or the revenue. Most on here have no idea why the share price remains where its at Problem #-1 is Doug. The ceo has a fudiciary duty to shareholders which in most opinions he has not upheld Problem #-2 Is short hedge fu ds, adam fudstain and a few bad apples like Jeffries. They collude daily to propogate lies all over the internet about srpt and naked shorting is rampant. They can do this in perpetuity to scare inveators and make it look like the daily drops are a natural part of investing With problem 1, theres not much you can do. With problem 2, theres not much you can do. Only one person can stop problem number 2 but problem number 3 is that person is problem number 1 Capice?

1 · Reply

Evagaminska Feb. 4 at 12:56 AM

$NVO What actually is happening with biotech companies and big pharma? We aren’t getting timely communication from clowns at FDA, delay approval like for rare diseases $SRPT $CAPR Not much MNA It’s seem innovation is dead and now with Makary,Prasad & Oz the whole medical&health insurance system is collapsing?

1 · Reply

Thaigrlsrk Feb. 3 at 11:32 PM

$SRPT 🚨 Breaking News! 🚨 The U.S. House of Representatives passed a government funding package that includes key priorities for people living with neuromuscular diseases and their families, representing a major step forward for access to care, research, and more. Now, the bill heads to the President’s desk, where we expect him to sign it into law. Your engagement with your lawmakers in both Washington, DC and all across the nation truly made a difference in getting policies passed that are vital for neuromuscular community and their families, such as: ➡️ Strong medical research funding for the National Institutes of Health (NIH) and across the federal government. ➡️ Supports for children living with neuromuscular disease and their families by including the Accelerating Kids’ Access to Care Act and reauthorizing the Rare Pediatric Disease Priority Review Voucher (PRV) program. ➡️ Much more!

2 · Reply

Find_the_Cure Feb. 3 at 11:28 PM

$SRPT AH is so CONTRIVED!!!! It’s actually quite funny yet preposterous. Seriously!!!

0 · Reply

Bonkersfor_chips Feb. 3 at 11:00 PM

$SRPT I want to believe that the worse is behind us and we will rise again. BUT, my patience is running thin. Why should I stay?

1 · Reply

Bonkersfor_chips Feb. 3 at 10:57 PM

$SRPT yet we down, bruh...

0 · Reply

Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript

Jan 26, 2026, 8:53 AM EST - 8 days ago

Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys

Jan 26, 2026, 8:10 AM EST - 8 days ago

Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows

Jan 26, 2026, 8:00 AM EST - 8 days ago

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

Jan 23, 2026, 4:05 PM EST - 11 days ago

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

Jan 16, 2026, 9:25 AM EST - 18 days ago

Sarepta Therapeutics: Is Elevidys A Bust?

Jan 12, 2026, 2:36 PM EST - 22 days ago

Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 11:58 AM EST - 22 days ago

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Jan 12, 2026, 9:30 AM EST - 22 days ago

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Jan 7, 2026, 8:30 AM EST - 27 days ago

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

Jan 5, 2026, 8:30 AM EST - 4 weeks ago

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 31, 2025, 5:20 PM EST - 4 weeks ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 17, 2025, 6:48 AM EST - 6 weeks ago

Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests

Dec 11, 2025, 7:00 AM EST - 7 weeks ago

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Nov 25, 2025, 12:07 PM EST - 2 months ago

Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk

Nov 25, 2025, 8:57 AM EST - 2 months ago

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Nov 24, 2025, 7:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

ARWR

Nov 24, 2025, 7:30 AM EST - 2 months ago

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Nov 14, 2025, 5:48 PM EST - 2 months ago

Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Nov 14, 2025, 2:54 PM EST - 2 months ago

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Nov 14, 2025, 2:08 PM EST - 2 months ago

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Nov 4, 2025, 1:39 PM EST - 3 months ago

Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026

Nov 4, 2025, 12:33 PM EST - 3 months ago

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Nov 4, 2025, 12:11 PM EST - 3 months ago

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It

Nov 4, 2025, 9:55 AM EST - 3 months ago

Sarepta Therapeutics shares plunge after disappointing trial data

Nov 4, 2025, 6:20 AM EST - 3 months ago

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Nov 4, 2025, 5:36 AM EST - 3 months ago

Sarepta Therapeutics, Inc. (SRPT) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:27 AM EST - 3 months ago

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Nov 3, 2025, 6:26 PM EST - 3 months ago

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Nov 3, 2025, 4:24 PM EST - 3 months ago

Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:05 PM EST - 3 months ago

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Oct 27, 2025, 4:05 PM EDT - 3 months ago

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Oct 23, 2025, 6:46 AM EDT - 3 months ago

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

BLSH DASH FLY IREN NEM OPEN QS

Oct 10, 2025, 11:49 AM EDT - 4 months ago

Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline

Oct 8, 2025, 11:19 AM EDT - 4 months ago

What's Going On Sarepta Stock On Wednesday?

Oct 3, 2025, 8:30 AM EDT - 4 months ago

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Sep 5, 2025, 9:00 AM EDT - 5 months ago

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

Aug 28, 2025, 6:20 AM EDT - 5 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN IONS MRNA

Aug 25, 2025, 3:11 AM EDT - 5 months ago

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

Aug 23, 2025, 7:08 AM EDT - 5 months ago

SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)

Aug 22, 2025, 12:12 PM EDT - 5 months ago

Sarepta Therapeutics: A Strong Opportunity Amidst The Panic

Aug 22, 2025, 9:50 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Aug 21, 2025, 7:00 AM EDT - 5 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

Aug 20, 2025, 3:30 PM EDT - 5 months ago

SRPT Update: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline

Aug 18, 2025, 12:01 PM EDT - 6 months ago

Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman

joselito_dominguez Feb. 4 at 8:27 AM

$SRPT If you’re invested in SRPT, the thesis is simple: execution + evidence. More long-term data, smarter risk management, and steady delivery.

0 · Reply

StocksCryptoNews Feb. 4 at 2:37 AM

0 · Reply

Maniacal_Laugh Feb. 4 at 2:26 AM

$SRPT they are both manipulating and naked shorting to keep a lid on the price

0 · Reply

Maniacal_Laugh Feb. 4 at 1:19 AM

$SRPT so in this case, a person just takes advantage of the manipulation

1 · Reply

Maniacal_Laugh Feb. 4 at 1:16 AM

1 · Reply

Evagaminska Feb. 4 at 12:56 AM

1 · Reply

Thaigrlsrk Feb. 3 at 11:32 PM

2 · Reply

Find_the_Cure Feb. 3 at 11:28 PM

$SRPT AH is so CONTRIVED!!!! It’s actually quite funny yet preposterous. Seriously!!!

0 · Reply

Bonkersfor_chips Feb. 3 at 11:00 PM

$SRPT I want to believe that the worse is behind us and we will rise again. BUT, my patience is running thin. Why should I stay?

1 · Reply

Bonkersfor_chips Feb. 3 at 10:57 PM

$SRPT yet we down, bruh...

0 · Reply

iCro93 Feb. 3 at 9:31 PM

$SRPT 10 millions USD inflow in last 3 trading days..

0 · Reply

Maniacal_Laugh Feb. 3 at 8:29 PM

$SRPT TBF Doug needs to change things up. Investigate short hedge funds. I agree something isnt right but its not all because of lack of potential. There is concerted effort here to naked short srpt literally on a daily basis. Doug should hire a private investigator. He sued the FDA so why not sue the ones manipulating the share price. These guys just put a lid on it any time srpt goes green. If they do this long enough it destroys not only the sp but market confidence. I remember one time reading goldman sachs and a few others did this for years to certain stocks. 👀🤷‍♂️

0 · Reply

Initiator1 Feb. 3 at 8:10 PM

$SRPT Is the story dead? I agree that based on the revenue multiple, Sarepta is probably the ost undervalued company in the biotech space. But why is the market not regaining confidence? Why is the short interest so high and why haven’t the shorts covered despite the stock being so low? Elevidys wasn’t pulled. 3-year Efficacy data is great. Sirolimus may help get non ambulatory back soon. FSHD and DM1 safety data is due soon. If all goes well, Sarepta could be doing $4BN+ In revenue by 2030. Heck, it could hit $3BN by 2028. $4BN @ 6.5x revenue multiple makes the company worth more than $25BN. But I guess the market believes none of that. I am genuinely keen to get answers.

2 · Reply

free2dream Feb. 3 at 7:45 PM

$SRPT there is serious value at this price. No Biotech comapny has over $1B sales and trades at $2B market cap. Failed to break $20 again, there is nothing to short here. Go short $SNDK and $MU those are parabolic. SRPT one day gap open in mid $50S

1 · Reply

Martinsucks Feb. 3 at 7:13 PM

$SRPT wow this one is truly pathetic..

1 · Reply

SugarSlim Feb. 3 at 6:35 PM

$SRPT One day y'all one day

1 · Reply

Find_the_Cure Feb. 3 at 6:26 PM

$SRPT The horror. The horror

1 · Reply

Checkburner Feb. 3 at 6:06 PM

$PYPL $SRPT the dude is a great guy to follow for shorts.

0 · Reply

Maniacal_Laugh Feb. 3 at 6:05 PM

$SRPT 786,000 shares SMH

0 · Reply

free2dream Feb. 3 at 5:31 PM

$SRPT go short fucking $SNDK thats where you'll make the money $SOXS

0 · Reply

Maniacal_Laugh Feb. 3 at 5:30 PM

$SRPT Nice hunt mms

0 · Reply

free2dream Feb. 3 at 5:30 PM

$SRPT COOL IT with the stupid posts, this company is helping children for the god sake, the posts here are pathetic. How do you cure a terminal disease ? You invest money to research it. FDA and the entire market is so hostile towards Sarepta , even though Sarepta just shared a very good data set.

1 · Reply

Market Cap	2.13B
Revenue (ttm)	1.90B
Net Income (ttm)	235.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	7.71
Profit Margin	12.37%
Debt to Equity Ratio	0.78

Volume	1,880,200
Avg Vol	3,062,260
Day's Range	N/A - N/A
Shares Out	104.79M
Stochastic %K	13%
Beta	0.48
Analysts	Sell
Price Target	$21.43